This study explores the association of symptomatic episodes of atrial fibrillation (AF) occurrence and long-term risk of thromboembolic complications in a retrospective setting.
The study population consists of the FinCV-dataset, which includes 7660 acute cardioversions for atrial fibrillation. The electronic patient records of FinCV-study patients are reviewed to collect data on anticoagulation, number of cardioversions as well as mortality and stroke data. We seek to explore the possible association between the frequency of AF paroxysms in low stroke risk patients and the occurrence of death, stroke and major bleed as well as the net clinical benefit of anticoagulation. Data collection is performed by reviewing electronic patient records.
Study Type
OBSERVATIONAL
Enrollment
1,300
Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
Turku University Hospital, Heart Center
Turku, Southwest Finland, Finland
Death
Death from any cause
Time frame: From the first cardioversion through study completion, an average of 6 years
Ischemic stroke or TIA (transient ischemic attack)
Ischemic stroke or TIA diagnosed by neurologist
Time frame: From the first cardioversion through study completion, an average of 6 years
Major Bleed
Major Bleeding complication according to ISTH (International Society on Thrombosis and Haemostasis)
Time frame: From the first cardioversion through study completion, an average of 6 years
Permanent oral anticoagulation
Initiation of permanent oral anticoagulation therapy, information on oral anticoaglation initiation done by reviewing electronic patient records
Time frame: From the first cardioversion through study completion, an average of 6 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.